Neuroscience. 2016 May 7. pii: S0306-4522(16)30145-2. doi: 10.1016/j.neuroscience.2016.05.006. [Epub ahead of print]
Xanthurenic acid is localized in neurons in the central nervous system.
Abstract
Kynurenine (KYN)
pathway metabolites (KPM) are thought to be synthesized mainly by
non-neuronal cells in the mammalian brain. KPM are of particular
interest because several studies demonstrated their implication in
various disorders of the nervous system.
Among KPM is xanthurenic acid (XA) deriving from the catabolism of 3-hydroxykynurenine. Based on its chemical structure, XA appears as a close analog of kynurenic acid (KYNA) which has been extensively investigated and is considered as a potent neuroprotective compound.
Contrary to kynurenine acid, XA has received little attention and its role in the brain remains not elucidated.
We have previously described several characteristics of XA, suggesting its possible involvement in neurotransmission. XA is also proposed as a potential modulator at glutamatergic synapses.
Here, we used a selective antibody against XA and various neuronal, glial and synaptic markers to show that XA is essentially localized in the soma and dendrites of brain neurons, but is absent from axonal compartments and terminal endings. Our results also reveal that XA-like immunoreactivity is not expressed by glial cells.
To double-check our findings, we have also used another XA antibody obtained from a commercial source to confirm the neuronal expression of XA. Together, our results suggest that, differently to several other KPM produced by glial cells, XA exhibits a neuronal distribution in the mouse brain.
Copyright © 2016 IBRO. Published by Elsevier Ltd. All rights reserved.
Among KPM is xanthurenic acid (XA) deriving from the catabolism of 3-hydroxykynurenine. Based on its chemical structure, XA appears as a close analog of kynurenic acid (KYNA) which has been extensively investigated and is considered as a potent neuroprotective compound.
Contrary to kynurenine acid, XA has received little attention and its role in the brain remains not elucidated.
We have previously described several characteristics of XA, suggesting its possible involvement in neurotransmission. XA is also proposed as a potential modulator at glutamatergic synapses.
Here, we used a selective antibody against XA and various neuronal, glial and synaptic markers to show that XA is essentially localized in the soma and dendrites of brain neurons, but is absent from axonal compartments and terminal endings. Our results also reveal that XA-like immunoreactivity is not expressed by glial cells.
To double-check our findings, we have also used another XA antibody obtained from a commercial source to confirm the neuronal expression of XA. Together, our results suggest that, differently to several other KPM produced by glial cells, XA exhibits a neuronal distribution in the mouse brain.
Copyright © 2016 IBRO. Published by Elsevier Ltd. All rights reserved.
KEYWORDS:
immunocytochemistry; kynurenine pathway; mouse brain; neuronal localization; xanthurenic acidXanthureenihappo on vahva inhibiittori entsyymille sepiapteriinireduktaasi (SPR), jota tarvitaan tetrahydrobiopteriinin de novo synteesiin.
Inga kommentarer:
Skicka en kommentar